Dosis Monitoring bei anti-TNF-Alpha Therapie bei rheumatoider Arthritis

Collaboration between the Immanuel Klinikum Bernau Herzzentrum Brandenburg, the Rheumazentrum Nord-Brandenburg and BioTeZ demonstrates new ways of treating rheumatoid arthritis. The results of the joint study are published in the current issue of the journal "Clinical and Experimental Rheumatology1".

Through the introduction of therapeutic antibodies, the treatment results for rheumatoid arthritis (RA) have been significantly improved over the past decade. However, cases of inadequate effectiveness remain, as well as side effects due to the associated strong immunosuppression, especially with high activity levels. One possibility for therapy optimization is the targeted, individual dose adjustment of the active ingredients for each patient. At the moment, all RA patients treated with the TNF-alpha inhibitor adulimumab received a pre-approved standard dose of 40 mg every 14 days without regard for existing differences in body weight, sex, health status, metabolism and age. As a result, some patients receive too high drug dose and other patients have too low drug levels.

Using the test (recoveryELISA from BioTeZ), it is now possible simultaneously quantify the concentrations of the therapeutic antibody adalimumab and the target antigen TNF alpha in the patient's serum during therapy (Zänker et al., 2017). The Figure 1 summarizes the results of the study, with the patients being divided into three Groups. DE: mehr lesen EN: read more

 

 

 

 

Preeclampsia Diagnostics

Preeclampsia is a serious disorder of human pregnancy with the risk of a premature birth and life-threatening blood pressure of the mother. HUDSON Institute, Australia established assay for early detection of preeclampsia. Read more…English or German Press Release

 

polystreptavidin coatings to functionalise surfaces, microfluidic systems, beads and more

BioTeZ Polystreptavidin R Coating Kit

Today’s biology for Lab-on-a-Chip-Systems, Microfluidic Chips, Microfluidic Devices, Beads or Magnetic Beads are often enhanced by streptavidin coatings to functionalise surfaces and micro structures. Streptavidin binds very tightly to the small molecule Biotin. Streptavidin coating of solid phase’s offers a universal immobilization principle for the detection and analysis of antibodies, proteins, peptides, DNA, RNA, PCR-fragments, haptens etc.

The BioTeZ Polystreptavidin R Coating Kit (Product Code: BTCK-MC) is useful for adsorptive coatings on microplates, beads, membranes etc. made of metal, nitrocellulose, ceramic, silicon, glass or plastics like Polystyrene, Polyethylene, Polypropylene, Polycarbonate, Poly(methyl methacrylate) PMMA or Polyamides with “Maximum Biotin Binding Capacity”.

Polystrept R combines the excellent binding capacity with a high chemo and thermo stability.Additional pre-coating serves to improve the outcome and especially for very inert surfaces to ensure high quality coatings with Polystreptavidin R.

Polystreptavidin R provides product consistency and helps to reduce variability in diagnostic assays. Test it; make the comparison of BioTeZ Polystreptavidin R Coating Kit and surface activated beads or other surface activations.

Typical applications where Polystreptavidin R is used: IVD assays, isolation and purification of biotinylated molecules, ligand coupling.

Seite 1 von 9

Beratung und Kontakt

   +49 30-94 89 21 30
  +49 30-94 94 50 9
   info@biotez.de

BioTeZ GmbH

Die BioTeZ Berlin-Buch GmbH ist ein Biotechnologie-Unternehmen und wurde 1992 gegründet. BioTeZ ist Partner der Forschung, der Pharmaindustrie und der Labordiagnostik.

  • Biodiagnostika
  • Oligonukleotide
  • Markierte Biomoleküle

Kontakt

BioTeZ Berlin Buch GmbH
Robert-Rössle-Strasse 10, Haus D 72
13125 Berlin - Germany

Tel: +49 30-9489-2130
Fax: +49 30-9494-509
E-Mail: info@biotez.de
www.biotez.de

Events

Meet BioTeZ at MEDICA, 13-16 Nov. 2017, Düsseldorf, Booth 3 G54. Get Information about diagnostics and biotechnological services we offer: Therapeutic Drug Monitoring, Mycotoxin and Vitamin Analysis, Oligonucleotides, Human Proteases Research, Streptavidin Coatings


Biologics and Biosimilars Congress 2017 BerlinBioTeZ will present the latest research results from collaboration projects at the 3rd Biologics and Biosimilars Congress (6-7 March 2017); Summarizing outcomes of therapeutic drug monitoring studies with Omalizumab/IgE, Adalimumab/TNF and provide insights into Alirocumab, Evolocumab/PCSK9 recoveryELISA projects